Tysabri toxic hepatic effects

[Guest guest]

Biogen Idec, Elan and FDA notified healthcare professionals of reports

of clinically significant liver injury, including markedly elevated

serum hepatic enzymes and elevated total bilirubin, occurred as early as

six days after the first dose of Tysabri. The combination of

transaminase elevations and elevated bilirubin without evidence of obstruction

is

recognized as an important predictor of severe liver injury that may

lead to death or the need for a liver transplant in some patients.

Tysabri should be discontinued in patients with jaundice or other evidence of

significant liver injury. Physicians should inform patients that

Tysabri may cause liver injury.

Read the complete 2008 MedWatch Safety Summary, including a link to the

manufacturer's Dear Healthcare Professional Letter and prescribing

information for Tysabri at: "

http://www.p1source.com/common/ads/click.asp?at=8 & a=2250 & c=762 & z=40 & u=64282